REXULTI®

Hold Company

OTSUKA

Learn More

Dosage and Administration

TABLET;ORAL

Specification

0.25MG; 0.5MG; 1MG; 2MG; 3MG; 4MG

Indication

REXULTI® is indicated for the adjunctive treatment of major depressive disorder (MDD) in adults, the treatment of schizophrenia in adults and children aged 13 years and older, and the treatment of dementia-related agitation due to Alzheimer's disease.

Use

Instructions for Use

API

BREXPIPRAZOLE

API Structure

We Supply

BREXPIPRAZOLE

Note:

In-house Standard
Facility GMP
DMF/CDE

null

Note:

null

null

Note:

null

Drug Patent

Patent No	Expiration Date
10307419	2032/10/12
7888362	2026/4/12
8349840	2026/4/12
8618109	2026/4/12
9839637	2026/4/12
RE48059	2028/12/23

API Patent

Patent No	Expiration Date
8349840	2026/4/12
8618109	2026/4/12
9839637	2026/4/12
RE48059	2028/12/23

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.